ARS Pharmaceuticals, Inc. (SPRY)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ARS Pharmaceuticals, Inc.
NASDAQ:SPRYHealthcare · Biotechnology
AHAfter hours+0.00%$3.05
Prev close$3.050.00%Close$3.050.00%Now$3.05
Close$3.05+0.00%
Mkt Cap$303.31M
Float48.99M
O/S99.45M
VOL2.42M sh
$ Vol$7.29M
RVOL1.45×
Inst Own91.2%
SI40.5%
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | 3.05 | 3.11 | 2.92 | 3.05 | 2,425,329 |
| Nov 2, 2026 | 3.40 | 3.49 | 2.91 | 3.05 | 2,128,820 |
| Oct 30, 2026 | 3.62 | 3.79 | 3.34 | 3.38 | 1,756,862 |
| Oct 29, 2026 | 3.70 | 3.90 | 3.63 | 3.66 | 2,044,368 |
| Oct 28, 2026 | 3.69 | 3.73 | 3.52 | 3.65 | 2,534,761 |
| Oct 27, 2026 | 3.92 | 3.95 | 3.64 | 3.73 | 1,643,512 |
| Oct 26, 2026 | 4.03 | 4.09 | 3.90 | 3.92 | 1,433,831 |
| Oct 23, 2026 | 4.28 | 4.28 | 4.00 | 4.03 | 1,522,196 |
| Oct 22, 2026 | 4.13 | 4.36 | 4.13 | 4.32 | 1,787,746 |
| Oct 21, 2026 | 4.32 | 4.42 | 4.17 | 4.18 | 1,010,610 |
| Oct 20, 2026 | 4.25 | 4.44 | 4.22 | 4.29 | 1,542,751 |
| Oct 19, 2026 | 4.07 | 4.32 | 4.00 | 4.23 | 1,509,044 |
| Oct 16, 2026 | 4.08 | 4.08 | 3.81 | 4.02 | 2,332,021 |
| Oct 15, 2026 | 3.99 | 4.09 | 3.94 | 4.07 | 2,220,134 |
| Oct 14, 2026 | 4.01 | 4.09 | 3.88 | 3.93 | 1,729,602 |
| Oct 13, 2026 | 4.18 | 4.18 | 4.00 | 4.05 | 1,546,825 |
| Oct 12, 2026 | 4.20 | 4.27 | 4.06 | 4.18 | 1,274,278 |
| Oct 9, 2026 | 4.53 | 4.55 | 4.20 | 4.23 | 1,258,396 |
| Oct 8, 2026 | 4.35 | 4.63 | 4.21 | 4.56 | 1,585,366 |
| Oct 7, 2026 | 4.24 | 4.40 | 4.20 | 4.36 | 1,297,977 |
Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
Not availableRatings Distribution
BUY4
HOLD6
SELL0
TOTAL10
Insider Trades
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Casale Donn | President and CEO | Grant/Award | 1.04M | -- | Oct 1, 2026 |
 Smith Margaret Ekins | Chief Commercial Officer | Grant/Award | 1.00M | -- | Sep 1, 2026 |
| Casale Donn | President and CEO | Grant/Award | 898.5K | -- | Jul 1, 2026 |
 Dadoo Rajeev | Director | Grant/Award | 30.0K | -- | Jun 24, 2026 |
 Kelly Michael | Director | Grant/Award | 30.0K | -- | Jun 24, 2026 |
 Shawver Laura | Director | Grant/Award | 30.0K | -- | Jun 24, 2026 |
Shareholders
91.2%
Institutional
(208)
8.4%
Insiderⓘ
(9)
9.1%
5%+ Owners
(2)
of which 5.2% rests on schedules older than 24 months (1 holder)
-
Unattributed (incl. retail)ⓘ
Institutional91.2%
Insider8.4%
5%+ Beneficial9.1%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
RA Capital Management, L.P. · also on 13F· may incl. warrants· filed Oct 2025 | 10.9M | 11.0% | 13D |
RA CAPITAL MANAGEMENT, L.P. | 10.9M | 10.9% | 13F |
Rubric Capital Management LP | 8.5M | 8.6% | 13F |
ORBIMED ADVISORS LLC | 8.3M | 8.3% | 13F |
Rubric Capital Management LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 8.0M | 8.0% | 13G |
DEERFIELD MANAGEMENT COMPANY, L.P. | 7.5M | 7.5% | 13F |
BlackRock, Inc. | 5.3M | 5.3% | 13F |
The Pratik Shah Living Trust dated June 15, 2011(1) 2. · may incl. warrants· stale · filed Jun 2024 | 5.2M | 5.2% | 13D |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Apr 2026 | 4.9M | 5.0% | 13G |
Tyro Capital Management LLC | 4.5M | 4.5% | 13F |
Sources: 13F, Form 4, 13D/13GO/S: 99.4M · as of 11 Aug 2026 · SEC cover page
Insiders & Institutional Holders
Insiders
- Casale DonnPresident and CEO
- Smith Margaret EkinsChief Commercial Officer
- Dadoo RajeevDirector
- Kelly MichaelDirector
- Shawver LauraDirector
- SAUNDERS BRENT LDirector
- SCHNEIDER PHILLIP MDirector
- Thompson Peter A.Director
- Shah PratikDirector
- RA CAPITAL MANAGEMENT, L.P.Director
About
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Key Metrics
Market Cap$303.31M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership91.19%
based on 99.45M shares outstanding
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
Country
US
USIPO DateDec 4, 2020
Shares Outstanding99.45M
Float48.99M
52-Week Range
$2.91$13.15
$3.05(1st percentile)
Volume
Average Daily Volume1.70M
2.43M today vs 1.70M avg(+43%)
30d Avg
1.70M
60d Avg
1.62M
90d Avg
1.64M
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...